In the 2000s, when the AIDS pandemic hit South Africa, we were seeing a lot of children dying from HIV. That was just before ...

Insmed said its phase 3b Encore study of Arikayce in mac lung disease met its main goal and all multiplicity-controlled secondary culture-conversion endpoints, with the clearest gains showing up in ...

In March 2026, Insmed reported positive Phase 3b ENCORE results showing ARIKAYCE added to standard multidrug therapy improved symptoms and culture conversion in patients with MAC lung disease who were ...

Wed, March 25, 2026 at 2:58 PM UTC Here is a fact that should reframe how you think about Insmed (NASDAQ:INSM) and its lung disease franchise: Japan has more patients with MAC lung disease than the ...

Shares of Insmed climbed after the company disclosed what it called positive topline results from a late-stage study of its treatment for certain lung infections. The stock rose 10%, to $150.02, in ...

—The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Respiratory Symptom ...

"These results are an exciting win for patients living with MAC lung disease and a powerful validation of ARIKAYCE's ability to deliver real clinical benefit as part of a multidrug treatment regimen," ...

Even after completing treatment for tuberculosis (TB), some patients may remain vulnerable to further lung infections. Scientists at A*STAR Infectious Diseases Labs (A*STAR IDL) have recently ...